167 related articles for article (PubMed ID: 15932563)
61. Prognostic value of serum tumor antigen CA19-9 after curative resection of colorectal cancer.
Park IJ; Choi GS; Jun SH
Anticancer Res; 2009 Oct; 29(10):4303-8. PubMed ID: 19846991
[TBL] [Abstract][Full Text] [Related]
62. Clinically aggressive pseudomyxoma peritonei: a variant of a histologically indolent process.
Mohamed F; Gething S; Haiba M; Brun EA; Sugarbaker PH
J Surg Oncol; 2004 Apr; 86(1):10-5. PubMed ID: 15048674
[TBL] [Abstract][Full Text] [Related]
63. Treatment of pseudomyxoma peritonei with two times--cytoreduction and hypertermic antiblastic peritoneal perfusion (HAPP).
De Simone M; Scuderi S; Vaira M; Costamagna D; Barone R; Fiorentini G; Dentico P; Caponi A; Ciaccio B; Caponi C; Ferri L; Martini E; Cantini S
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):25-8. PubMed ID: 16767902
[TBL] [Abstract][Full Text] [Related]
64. Critical analysis of treatment failure after complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from appendiceal mucinous neoplasms.
Yan TD; Bijelic L; Sugarbaker PH
Ann Surg Oncol; 2007 Aug; 14(8):2289-99. PubMed ID: 17541772
[TBL] [Abstract][Full Text] [Related]
65. Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Elias D; Honoré C; Ciuchendéa R; Billard V; Raynard B; Lo Dico R; Dromain C; Duvillard P; Goéré D
Br J Surg; 2008 Sep; 95(9):1164-71. PubMed ID: 18690633
[TBL] [Abstract][Full Text] [Related]
66. Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated by surgery alone.
Nissan A; Stojadinovic A; Shia J; Hoos A; Guillem JG; Klimstra D; Cohen AM; Minsky BD; Paty PB; Wong WD
J Clin Oncol; 2006 Sep; 24(25):4078-84. PubMed ID: 16943525
[TBL] [Abstract][Full Text] [Related]
67. Follow-up of ovarian and primary peritoneal carcinoma: the value of physical examination in patients with pretreatment elevated CA125 levels.
Menczer J; Chetrit A; Sadetzki S; Golan A; Levy T
Gynecol Oncol; 2006 Oct; 103(1):137-40. PubMed ID: 16564077
[TBL] [Abstract][Full Text] [Related]
68. Pseudomyxoma peritonei.
Smeenk RM; Verwaal VJ; Zoetmulder FA
Cancer Treat Rev; 2007 Apr; 33(2):138-45. PubMed ID: 17182192
[TBL] [Abstract][Full Text] [Related]
69. Biological variation and reference change values of CA 19-9, CEA, AFP in serum of healthy individuals.
Erden G; Barazi AO; Tezcan G; Yildirimkaya MM
Scand J Clin Lab Invest; 2008; 68(3):212-8. PubMed ID: 17926198
[TBL] [Abstract][Full Text] [Related]
70. Prognostic value of preoperative CEA, CA 19-9, CA 72-4, and AFP levels in gastric cancer.
Ucar E; Semerci E; Ustun H; Yetim T; Huzmeli C; Gullu M
Adv Ther; 2008 Oct; 25(10):1075-84. PubMed ID: 18821070
[TBL] [Abstract][Full Text] [Related]
71. The effect of maternal age, parity, and fetal sex on the amniotic fluid and maternal serum levels of CA 125, CA 19.9, CA 15.3, and CEA.
Tayyar M; Tutus A
Int J Fertil Womens Med; 1999; 44(5):256-9. PubMed ID: 10569455
[TBL] [Abstract][Full Text] [Related]
72. The second procedure combining complete cytoreductive surgery and intraperitoneal chemotherapy for isolated peritoneal recurrence: postoperative course and long-term outcome.
Brouquet A; Goéré D; Lefèvre JH; Bonnet S; Dumont F; Raynard B; Elias D
Ann Surg Oncol; 2009 Oct; 16(10):2744-51. PubMed ID: 19626375
[TBL] [Abstract][Full Text] [Related]
73. Negative serum carcinoembryonic antigen has insufficient accuracy for excluding recurrence from patients with Dukes C colorectal cancer: analysis with likelihood ratio and posttest probability in a follow-up study.
Hara M; Kanemitsu Y; Hirai T; Komori K; Kato T
Dis Colon Rectum; 2008 Nov; 51(11):1675-80. PubMed ID: 18633674
[TBL] [Abstract][Full Text] [Related]
74. Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies.
Mehta J; Prabhu R; Eshpuniyani P; Kantharia C; Supe A
Trop Gastroenterol; 2010; 31(3):190-4. PubMed ID: 21560524
[TBL] [Abstract][Full Text] [Related]
75. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
[TBL] [Abstract][Full Text] [Related]
76. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma: non-mucinous tumour associated with an improved survival.
Yan TD; Chu F; Links M; Kam PC; Glenn D; Morris DL
Eur J Surg Oncol; 2006 Dec; 32(10):1119-24. PubMed ID: 16887321
[TBL] [Abstract][Full Text] [Related]
77. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients.
Laessig D; Nagel D; Heinemann V; Untch M; Kahlert S; Bauerfeind I; Stieber P
Anticancer Res; 2007; 27(4A):1963-8. PubMed ID: 17649806
[TBL] [Abstract][Full Text] [Related]
78. Value of tumor markers in diagnosing and monitoring colorectal cancer and strategies for further improvement: analysis of 130 cases.
Chen C; Chen LQ; Yang GL; Li Y
Ai Zheng; 2007 Nov; 26(11):1221-6. PubMed ID: 17991322
[TBL] [Abstract][Full Text] [Related]
79. Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas.
Shoji F; Yoshino I; Yano T; Kometani T; Ohba T; Kouso H; Takenaka T; Miura N; Okazaki H; Maehara Y
Cancer; 2007 Dec; 110(12):2793-8. PubMed ID: 17941001
[TBL] [Abstract][Full Text] [Related]
80. [Treatment of the peritoneal carcinomatosis by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy (IHPC): postoperative morbidity and mortality and short-term follow-up].
Minicozzi A; Borzellino G; Momo EN; Segattini C; Pitoni F; Steccanella F; De Manzoni G
Ann Ital Chir; 2008; 79(4):231-9. PubMed ID: 19093624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
